Drugs / Fexofenadine HCI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00547768 | Nov → Dec 2002 | allergic disease | Sanofi | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2005-09-12 | Prasco LLC | Prasco and sanofi-aventis Sign a Distribution and Supply Agreement for Authorized Generic versions of Allegra® (fexofenadine HCl) prasco.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fexofenadine HCI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00547768 ↗ |
| Known as | fexofenadine HCl | “Compare the effect of a single dose of fexofenadine HCl 180 mg plus orange juice versus placebo plus orange juice on the change from baseline (pre-dose) in histamine skin flares.” NCT00547768 ↗ |